NCT03744403View on ClinicalTrials.gov

A Study of CS1001 in Subjects with Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

October 31, 2020

Study Completion Date

July 21, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

CS1001

In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.

Trial Locations (1)

78229

NEXT Oncology, San Antonio

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY